Status: Recruiting
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).
Participants needed: 50
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: BioPhoenix Co., Ltd.Updated: Nov 24, 2025Locations: 1
Eligibility criteria
Male or female ages ≥18 and ≤ 65 years. [+18]
Has had any other prior organ transplantation. [+15]